Risk Reduction for the Acquired Immunodeficiency Syndrome Among Intravenous Drug Users

  1. DON C. DES JARLAIS, Ph.D.;
  2. SAMUEL R. FRIEDMAN, Ph.D.; and
  3. WILLIAM HOPKINS, M.A.
  1. New York, New York

    Abstract

    Intravenous drug users are the second largest risk group for the acquired immunodeficiency syndrome (AIDS) and a bridge to two other groups: children and heterosexual partners. In the absence of effective treatment or vaccines, control of the epidemic among drug users will rely on efforts to reduce needle sharing. However, the traditional image of intravenous drug users leads one to expect little or no risk reduction. We review characteristics of AIDS as a disease that impede efforts at risk reduction among drug users and report on current risk reduction among intravenous drug users in New York City. There has been a sustained increase in the demand for new, unused needles, as shown in the emergence of "resealed" needles and in interviews with persons selling needles in illicit drug-purchasing areas.

    Article and Author Information

    • ▸From the New York State Division of Substance Abuse Services and Narcotic and Drug Research, Inc.; New York, New York.

    • ▸Requests for reprints should be addressed to Don C. Des Jarlais, Ph.D.; State of New York, Division of Substance Abuse Services, Two World Trade Center, Room 6754, 67th Floor; New York, NY 10047.

    | Table of Contents
    Most Read Most Read
    Most Commented Most Commented On
    Annals in the News Annals in the News
    Clinical Trials Clinical Trials
    Comparative Effectiveness Comparative Effectiveness
    Hospital Medicine Hospital Medicine
    • Advertisement
    • Advertisement